NASDAQ:SNDX Syndax Pharmaceuticals (SNDX) Stock Price, News & Analysis $12.95 -0.15 (-1.15%) Closing price 03/14/2025 04:00 PM EasternExtended Trading$13.27 +0.32 (+2.48%) As of 03/14/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Syndax Pharmaceuticals Stock (NASDAQ:SNDX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Syndax Pharmaceuticals alerts:Sign Up Key Stats Today's Range$12.86▼$13.3250-Day Range$12.53▼$16.3852-Week Range$12.06▼$25.07Volume767,111 shsAverage Volume2.26 million shsMarket Capitalization$1.11 billionP/E RatioN/ADividend YieldN/APrice Target$36.00Consensus RatingModerate Buy Company OverviewSyndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Read More… Remove Ads Syndax Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreSNDX MarketRank™: Syndax Pharmaceuticals scored higher than 75% of companies evaluated by MarketBeat, and ranked 259th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingSyndax Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSyndax Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Syndax Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Syndax Pharmaceuticals are expected to decrease in the coming year, from ($3.72) to ($4.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Syndax Pharmaceuticals is -3.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syndax Pharmaceuticals is -3.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyndax Pharmaceuticals has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Syndax Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted23.46% of the float of Syndax Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSyndax Pharmaceuticals has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Syndax Pharmaceuticals has recently decreased by 10.90%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSyndax Pharmaceuticals does not currently pay a dividend.Dividend GrowthSyndax Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.12 Percentage of Shares Shorted23.46% of the float of Syndax Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSyndax Pharmaceuticals has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Syndax Pharmaceuticals has recently decreased by 10.90%, indicating that investor sentiment is improving significantly. News and Social Media2.1 / 5News Sentiment0.70 News SentimentSyndax Pharmaceuticals has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Syndax Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 6 people have searched for SNDX on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Syndax Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Syndax Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $336,086.00 in company stock.Percentage Held by InsidersOnly 4.10% of the stock of Syndax Pharmaceuticals is held by insiders.Read more about Syndax Pharmaceuticals' insider trading history. Receive SNDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SNDX Stock News HeadlinesResearch Analysts Issue Forecasts for SNDX FY2025 EarningsMarch 8, 2025 | americanbankingnews.comSyndax Pharmaceuticals (NASDAQ:SNDX) Given "Buy" Rating at HC WainwrightMarch 7, 2025 | americanbankingnews.comNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. March 15, 2025 | Porter & Company (Ad)What is B. Riley's Forecast for SNDX Q3 Earnings?March 7, 2025 | americanbankingnews.comBrokers Set Expectations for SNDX Q1 EarningsMarch 7, 2025 | americanbankingnews.comQ1 Earnings Forecast for SNDX Issued By HC WainwrightMarch 7, 2025 | americanbankingnews.comCitigroup Has Lowered Expectations for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock PriceMarch 6, 2025 | americanbankingnews.comSyndax Pharmaceuticals Reports $7.7 Million in Initial Revenue from Revuforj® Launch and Provides Business UpdateMarch 5, 2025 | nasdaq.comSee More Headlines SNDX Stock Analysis - Frequently Asked Questions How have SNDX shares performed this year? Syndax Pharmaceuticals' stock was trading at $13.22 at the beginning of the year. Since then, SNDX shares have decreased by 2.0% and is now trading at $12.95. View the best growth stocks for 2025 here. How were Syndax Pharmaceuticals' earnings last quarter? Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) posted its earnings results on Monday, March, 3rd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.79. The firm earned $7.68 million during the quarter, compared to the consensus estimate of $86.32 million. When did Syndax Pharmaceuticals IPO? Syndax Pharmaceuticals (SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers. Who are Syndax Pharmaceuticals' major shareholders? Top institutional investors of Syndax Pharmaceuticals include Vanguard Group Inc. (5.72%), Wellington Management Group LLP (4.96%), Soleus Capital Management L.P. (2.92%) and Avoro Capital Advisors LLC (2.67%). Insiders that own company stock include Michael A Metzger, Neil Gallagher, Dennis Podlesak, William Meury, Pierre Legault, Keith Katkin, Briggs Morrison and Peter Ordentlich. View institutional ownership trends. How do I buy shares of Syndax Pharmaceuticals? Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Syndax Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Syndax Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Novo Nordisk A/S (NVO) and ServiceNow (NOW). Company Calendar Last Earnings3/03/2025Today3/14/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SNDX CIK1395937 Webwww.syndax.com Phone(781) 419-1400Fax781-419-1420Employees110Year FoundedN/APrice Target and Rating Average Stock Price Target$36.00 High Stock Price Target$51.00 Low Stock Price Target$16.00 Potential Upside/Downside+178.0%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($3.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-209,360,000.00 Net MarginsN/A Pretax Margin-1,856.64% Return on Equity-64.34% Return on Assets-57.72% Debt Debt-to-Equity RatioN/A Current Ratio6.99 Quick Ratio6.99 Sales & Book Value Annual Sales$23.68 million Price / Sales47.04 Cash FlowN/A Price / Cash FlowN/A Book Value$6.53 per share Price / Book1.98Miscellaneous Outstanding Shares86,024,000Free Float81,858,000Market Cap$1.11 billion OptionableOptionable Beta0.92 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:SNDX) was last updated on 3/15/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syndax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.